Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer.
Thyroid
; 17(1): 53-8, 2007 Jan.
Article
en En
| MEDLINE
| ID: mdl-17274750
ABSTRACT
OBJECTIVE:
We assessed the feasibility and efficacy of dendritic cell (DC) therapy for advanced thyroid papillary and follicular cancer.DESIGN:
Six Japanese patients (2 men and 4 women; aged 46-72 years, mean 60 years), who were diagnosed as advanced thyroid cancer with refractory distant metastases (papillary, n=5; follicular, n=1), were enrolled. Patients were first vaccinated weekly for 4 weeks with 10(7) autologous tumor lysate-pulsed monocyte-derived mature DCs followed by fortnightly vaccinations for 8 weeks (total=8 vaccinations). Lowdose (350 KIU) interleukin-2 was also administered for 3 days at each vaccination. Clinical response, adverse effects, delayed-type hypersensitivity skin testing (DTH), and IFN-( ) production by peripheral CD3(+) lymphocytes were evaluated. MAINOUTCOME:
Of the 6 patients, disease was assessed as stable in 2 and as progressive in 4. No adverse events were observed. Results of DTH and IFN-( ) production in peripheral lymphocytes did not correlate to the clinical response.CONCLUSIONS:
DC immunotherapy could be administered to patients with thyroid papillary or follicular cancer without substantial side effects.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Células Dendríticas
/
Neoplasias de la Tiroides
/
Carcinoma Papilar Folicular
/
Vacunas contra el Cáncer
/
Neoplasias Pulmonares
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Thyroid
Asunto de la revista:
ENDOCRINOLOGIA
Año:
2007
Tipo del documento:
Article
País de afiliación:
Japón